Authors


Nicola O'Connell

Latest:

Moorfields research provides hope for choroideremia cure

Preliminary research has shown that ataluren is effective in overriding the nonsense mutation in choroideremia patients, however, further research is needed.


Thomas A. Albini, MD

Latest:

Case #2: Impressions and Clinical Insights

A retina specialist discusses impressions and key take away points from patient case.





David S. Boyer, MD

Latest:

Innovative suprachoroidal injection reduces diabetic retinopathy complications

Breakthrough suprachoroidal injection technique offers promising treatment for diabetic retinopathy, reducing visual threatening complications from 37% to 4% with minimal inflammation and office-based procedure.


Dr. Michal S. Nowak

Latest:

Review of the epidemiology of diabetic retinopathy

The prevalence of visual impairment and blindness caused by diabetic retinopathy is increasing worldwide. Early recognition, perhaps via a screening programme, and timely management would be of benefit.


Dr. Andrzej Grzybowski

Latest:

Review of the epidemiology of diabetic retinopathy

The prevalence of visual impairment and blindness caused by diabetic retinopathy is increasing worldwide. Early recognition, perhaps via a screening programme, and timely management would be of benefit.





Malvika Arya, BS

Latest:

Parafoveal retinal vessel density assessment by OCTA in healthy eyes

Study aims to identify methodology for least amount of variation, greatest test-retest reliability


A. Yasin Alibhai, MD

Latest:

Parafoveal retinal vessel density assessment by OCTA in healthy eyes

Study aims to identify methodology for least amount of variation, greatest test-retest reliability


Carl B. Rebhun, BA

Latest:

Parafoveal retinal vessel density assessment by OCTA in healthy eyes

Study aims to identify methodology for least amount of variation, greatest test-retest reliability


Xuejing Chen, MD

Latest:

Parafoveal retinal vessel density assessment by OCTA in healthy eyes

Study aims to identify methodology for least amount of variation, greatest test-retest reliability


Elias Reichel, MD

Latest:

Parafoveal retinal vessel density assessment by OCTA in healthy eyes

Study aims to identify methodology for least amount of variation, greatest test-retest reliability


Caroline R. Baumal, MD

Latest:

Take-Home Points for the Treatment of AMD and DME

David A. Eichenbaum, MD, FASRS and Caroline Baumal, MD provide take-home messages to providers treating AMD and DME.


Andre J. Witkin, MD

Latest:

Parafoveal retinal vessel density assessment by OCTA in healthy eyes

Study aims to identify methodology for least amount of variation, greatest test-retest reliability


Jay S. Duker, MD

Latest:

Parafoveal retinal vessel density assessment by OCTA in healthy eyes

Study aims to identify methodology for least amount of variation, greatest test-retest reliability





Christine N. Kay, MD

Latest:

CTS 2025: Christine Kay, MD, on OPGx-LCA5 clinical results translated into real-life changes

Phase 1/2 interim results highlight real-world functional enhancements in patients with severe LCA5-related Leber congenital amaurosis.



Netan Choudhry, MD

Latest:

The subthreshold laser’s role in retinal vascular disease

Combination therapy benefits from laser in the mix for DME, other conditions


Munir Escaf, MD

Latest:

Laser therapy may offer fast-acting option for CSR resolution

Patients tolerate therapy well; high safety profile allows re-treatment as necessary


Alex Delaney-Gesing

Latest:

Update on FDA approval of XIPERE for macular edema associated with uveitis from Bausch + Lomb

Bausch + Lomb's Yolande Barnard shares an update on the FDA approval of XIPERE for the treatment of macular edema associated with uveitis.


OT Staff Reports

Latest:

Comparing suitable naïve versus pre-treated DME patients

Javier Zarranz-Ventura MD, PhD, FEBO, discusses the key highlights from his presentation on a clinical investigation of suitable naïve versus pre-treated DME patients, and what it means for future research.


Rishi P. Singh, MD

Latest:

ARVO 2025: Rishi Singh, MD, discusses real-world clinical outcomes in patients with DME

In an analysis of the IRIS database, investigators assessed almost 1,200 eyes that had been treated with faricimab.


© 2025 MJH Life Sciences

All rights reserved.